Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of BR3006 (Dapagliflozin/Pioglitazone/Metformin FDC) vs Components
NCT06890286Phase 1Completed
- Sponsor
- Boryung
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin, pioglitazone and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Dec 2024; status: completed.
02
Drugs
dapagliflozinpioglitazoneliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06890286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890286.